Validity of the Updated Rx-Risk Index as a Disease Identification and Risk-Adjustment Tool for Use in Observational Health Studies.

Imaina Widagdo, Mhairi Kerr, Lisa Kalisch Ellett, Clement Schlegel, Elham Sadeqzadeh, Alvin Wang, Allison Louise Clarke, Nicole Pratt
Author Information
  1. Imaina Widagdo: Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
  2. Mhairi Kerr: Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
  3. Lisa Kalisch Ellett: Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
  4. Clement Schlegel: Data and Analytics Branch, Health Economics and Research Division, Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
  5. Elham Sadeqzadeh: Data and Analytics Branch, Health Economics and Research Division, Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
  6. Alvin Wang: Data and Analytics Branch, Health Economics and Research Division, Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
  7. Allison Louise Clarke: Data and Analytics Branch, Health Economics and Research Division, Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
  8. Nicole Pratt: Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.

Abstract

Purpose: Identifying patient health conditions in observational studies is essential for accurately measuring healthcare practices and planning effective health policy interventions. This analysis evaluates the validity of the Rx-Risk Index, a tool that uses medication dispensing data to identify patient comorbidities and measure overall health. We examined an updated version of the Rx-Risk Index, reflecting changes in treatment practices, to assess its validity as a tool for identifying specific health conditions and as a measure of overall health to aid in risk adjustment in observational studies.
Patients and Methods: We conducted a validation study using two Australian linked health datasets, the Person-Level Integrated Data Asset (PLIDA) and the National Health Data Hub (NHDH), from 2010 to 2018, focusing on individuals aged 65 years or older. The sensitivity, specificity, PPV/NPV, Cohen's kappa, and F1 scores were used to assess agreement between Rx-Risk Index conditions and two reference standards: patient self-reported conditions and hospital diagnosis. The Rx-Risk Index's predictive validity for one-year mortality was also evaluated using logistic regression, with model fit assessed by AIC and c-statistic.
Results: Data were analysed from 3,959 individuals in PLIDA and 157,709 individuals in NHDH. The Rx-Risk Index showed high sensitivity (���75%) for diabetes, chronic airways disease, hyperlipidemia, and epilepsy against both self-reported conditions and hospital diagnoses. However, hyperlipidemia and hypertension showed lower specificity (<70%). High PPVs (���78%) were observed for diabetes and renal failure. The agreement between the Rx-Risk Index and self-reported conditions was stronger (Cohen's kappa: 0.41-0.81 for 7 conditions) than between Rx-Risk Index and ICD10-AM diagnoses (kappa: 0.73 for one condition). The Rx-Risk Index was a strong predictor of one-year mortality, with c-statistic of 0.820 (95% CI: 0.817-0.825).
Conclusion: Selected Rx-Risk Index conditions are reasonable proxies for identifying specific conditions, particularly those requiring pharmacological management. The Rx-Risk Index was a strong predictor of one-year mortality, suggesting it is a valid measure of overall health. This study demonstrates the Rx-Risk Index's potential to enhance disease classification and risk adjustment in observational studies, supporting informed decision-making in health policy planning.

Keywords

References

  1. Plast Reconstr Surg. 2010 Aug;126(2):619-625 [PMID: 20679844]
  2. Med Care. 2003 Jun;41(6):761-74 [PMID: 12773842]
  3. J Clin Epidemiol. 1992 Feb;45(2):197-203 [PMID: 1573438]
  4. Intern Emerg Med. 2015 Jun;10(4):517-24 [PMID: 25711312]
  5. BMC Geriatr. 2020 Aug 10;20(1):283 [PMID: 32778067]
  6. BMJ Open. 2018 Apr 13;8(4):e021122 [PMID: 29654048]
  7. Int J Epidemiol. 2000 Oct;29(5):891-8 [PMID: 11034974]
  8. J Clin Epidemiol. 2011 Feb;64(2):223-8 [PMID: 21172602]
  9. Allergol Immunopathol (Madr). 2013 Jan-Feb;41(1):54-9 [PMID: 23036443]
  10. J Math Psychol. 2000 Mar;44(1):62-91 [PMID: 10733858]
  11. PLoS One. 2020 Oct 16;15(10):e0240899 [PMID: 33064757]
  12. J Epidemiol Community Health. 2014 Mar;68(3):283-7 [PMID: 24248997]
  13. BMJ Open. 2022 May 2;12(5):e057823 [PMID: 35501100]
  14. Aust N Z J Public Health. 2009 Apr;33(2):126-30 [PMID: 19413854]
  15. Med Care. 2006 Aug;44(8):793-7 [PMID: 16862043]

MeSH Term

Humans
Aged
Male
Female
Comorbidity
Australia
Risk Adjustment
Risk Assessment
Aged, 80 and over
Observational Studies as Topic
Logistic Models
Reproducibility of Results

Word Cloud

Created with Highcharts 10.0.0Rx-RiskIndexconditionshealthobservationalvalidity0patientstudiesmeasureoverallriskadjustmentstudyDataindividualsself-reportedone-yearmortalitydiseasepracticesplanningpolicytooldataassessidentifyingspecificusingtwoPLIDAHealthNHDHsensitivityspecificityCohen'sagreementhospitalIndex'spredictivec-statisticshoweddiabeteshyperlipidemiadiagnoseskappa:strongpredictorclassificationPurpose:IdentifyingessentialaccuratelymeasuringhealthcareeffectiveinterventionsanalysisevaluatesusesmedicationdispensingidentifycomorbiditiesexaminedupdatedversionreflectingchangestreatmentaidPatientsMethods:conductedvalidationAustralianlinkeddatasetsPerson-LevelIntegratedAssetNationalHub20102018focusingaged65yearsolderPPV/NPVkappaF1scoresusedreferencestandards:diagnosisalsoevaluatedlogisticregressionmodelfitassessedAICResults:analysed3959157709high���75%chronicairwaysepilepsyHoweverhypertensionlower<70%HighPPVs���78%observedrenalfailurestronger41-0817ICD10-AM73onecondition82095%CI:817-0825Conclusion:Selectedreasonableproxiesparticularlyrequiringpharmacologicalmanagementsuggestingvaliddemonstratespotentialenhancesupportinginformeddecision-makingValidityUpdatedDiseaseIdentificationRisk-AdjustmentToolUseObservationalStudiespharmacoepidemiologyprescriptionclaims

Similar Articles

Cited By